Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 7/20 | 0.93 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.93 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.93 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.93 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.93 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.93 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.82 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.81 |
| ▸ | PRCP | P42785 | 5/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15354906 | 1.00 | CYP3A4 (0.93) | CYP3A4CYP2C9NR1I2KCNH2ABCB11 | |
| SCHEMBL10145022 | 1.00 | CYP3A4 (0.93) | CYP3A4CYP2C9NR1I2KCNH2ABCB11 | |
| SCHEMBL15274574 | 1.00 | CYP3A4 (0.93) | CYP3A4CYP2C9NR1I2KCNH2ABCB11 | |
| SCHEMBL9912086 | 1.00 | CYP3A4 (0.93) | CYP3A4CYP2C9NR1I2KCNH2ABCB11 | |
| SCHEMBL9912085 | 0.98 | CYP3A4 (0.89) | CYP3A4CYP2C9NR1I2KCNH2ABCB11 | |
| SCHEMBL2757116 | 0.98 | CYP3A4 (0.89) | CYP3A4CYP2C9NR1I2KCNH2ABCB11 | |
| Daclatasvir SCHEMBL21531495 | 0.96 | CYP3A4 (1.00) | CYP3A4CYP2C9NR1I2KCNH2ABCB11 | |
| Daclatasvir SCHEMBL21531497 | 0.96 | CYP3A4 (1.00) | CYP3A4CYP2C9NR1I2KCNH2ABCB11 | |
| Daclatasvir SCHEMBL12175169 | 0.96 | CYP3A4 (1.00) | CYP3A4CYP2C9NR1I2KCNH2ABCB11 | |
| Daclatasvir SCHEMBL21531496 | 0.96 | CYP3A4 (1.00) | CYP3A4CYP2C9NR1I2KCNH2ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2808325-A1 | Substituted azoles, anti-viral active ingredient, pharmaceutical composition, method for the production and use thereof | Alla Chem, LLC. (US) | 2014-12-03 | — | — | EP | disclosed |
| EP-2808325-A1 | Substituted azoles, anti-viral active ingredient, pharmaceutical composition, method for the production and use thereof | Alla Chem, LLC. (US) | 2014-12-03 | — | — | EP | disclosed |
| EP-2657231-A2 | SUBSTITUTED AZOLES, ANTI-VIRAL ACTIVE INGREDIENT, PHARMACEUTICAL COMPOSITION, METHOD FOR THE PRODUCTION AND USE THEREOF | Ivachtchenko, Alexandre Vasilievich (US) | 2013-10-30 | — | — | EP | disclosed |
| EP-2657231-A2 | SUBSTITUTED AZOLES, ANTI-VIRAL ACTIVE INGREDIENT, PHARMACEUTICAL COMPOSITION, METHOD FOR THE PRODUCTION AND USE THEREOF | Ivachtchenko, Alexandre Vasilievich (US) | 2013-10-30 | — | — | EP | disclosed |
| US-20130253008-A1 | SUBSTITUTED AZOLES, ANTIVIRAL ACTIVE COMPONENT, PHARMACEUTICAL COMPOSITION, METHOD FOR PREPARATION AND USE THEREOF | ALLA CHEM LLC (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130253008-A1 | SUBSTITUTED AZOLES, ANTIVIRAL ACTIVE COMPONENT, PHARMACEUTICAL COMPOSITION, METHOD FOR PREPARATION AND USE THEREOF | ALLA CHEM LLC (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130253008-A1 | SUBSTITUTED AZOLES, ANTIVIRAL ACTIVE COMPONENT, PHARMACEUTICAL COMPOSITION, METHOD FOR PREPARATION AND USE THEREOF | ALLA CHEM LLC (US) | 2013-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130253008-A1 | SUBSTITUTED AZOLES, ANTIVIRAL ACTIVE COMPONENT, PHARMACEUTICAL COMPOSITION, METHOD FOR PREPARATION AND USE THEREOF | HCCS, EIF2AK2, HAVCR2 | CYP3A4 20/4885CYP2C9 51/4885NR1I2 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.